MX2018006370A - Inhibidores de proteina quinasa, metodo de preparacion y su uso medico. - Google Patents
Inhibidores de proteina quinasa, metodo de preparacion y su uso medico.Info
- Publication number
- MX2018006370A MX2018006370A MX2018006370A MX2018006370A MX2018006370A MX 2018006370 A MX2018006370 A MX 2018006370A MX 2018006370 A MX2018006370 A MX 2018006370A MX 2018006370 A MX2018006370 A MX 2018006370A MX 2018006370 A MX2018006370 A MX 2018006370A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- present
- preparation
- medical use
- mesomer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
Abstract
La presente invención proporciona compuestos como se muestran en la fórmula I o un tautómero, un mesómero, un racemato, un enantiómero, un diastereómero, un compuesto deuterado, un profármaco o sus mezclas, o una sal o solvato aceptable farmacéuticamente del compuesto como se muestran en la fórmula I o un tautómero, un mesómero, un racemato, un enantiómero, un diastereómero, un compuesto deuterado, un profármaco o sus mezclas, en donde, R1 a R7 son tal como se definen en la descripción. La presente invención proporciona además un método de preparación y un uso médico de los compuestos. Los compuestos de la presente invención tienen una actividad superior o equivalente al fármaco candidato LY2835219 actualmente en ensayo clínico de fase III, y algunos de los compuestos muestran una selectividad mejor. Además, los compuestos preferidos exhiben una absorción buena y una distribución de sangre cerebral buena cuando se administran por vía oral. Los compuestos de la presente invención muestran de este modo una promesa para el desarrollo de nuevos fármacos para el tratamiento de enfermedades asociadas con la proliferación celular, particularmente tumores cerebrales, que proporcionan nuevas opciones para los médicos y los pacientes.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510856641.1A CN106810536A (zh) | 2015-11-30 | 2015-11-30 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
| PCT/CN2016/107455 WO2017092635A1 (zh) | 2015-11-30 | 2016-11-28 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018006370A true MX2018006370A (es) | 2018-09-24 |
Family
ID=58796287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018006370A MX2018006370A (es) | 2015-11-30 | 2016-11-28 | Inhibidores de proteina quinasa, metodo de preparacion y su uso medico. |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11091476B2 (es) |
| EP (1) | EP3385262B1 (es) |
| JP (2) | JP6921101B2 (es) |
| KR (1) | KR20180083421A (es) |
| CN (3) | CN106810536A (es) |
| AU (1) | AU2016365366B2 (es) |
| BR (1) | BR112018010879A2 (es) |
| CA (1) | CA3002884A1 (es) |
| CO (1) | CO2018005854A2 (es) |
| DK (1) | DK3385262T3 (es) |
| ES (1) | ES2928169T3 (es) |
| HU (1) | HUE060152T2 (es) |
| IL (1) | IL259711B (es) |
| MA (1) | MA42341B2 (es) |
| MX (1) | MX2018006370A (es) |
| PH (1) | PH12018550049A1 (es) |
| PT (1) | PT3385262T (es) |
| RU (1) | RU2749437C2 (es) |
| UA (1) | UA124001C2 (es) |
| WO (1) | WO2017092635A1 (es) |
| ZA (1) | ZA201803531B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106810536A (zh) | 2015-11-30 | 2017-06-09 | 甘李药业股份有限公司 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
| EP3700908A1 (en) | 2017-10-27 | 2020-09-02 | Fresenius Kabi Oncology Ltd | An improved process for the preparation of ribociclib and its salts |
| CN112334451A (zh) | 2018-02-15 | 2021-02-05 | 诺维逊生物股份有限公司 | 作为激酶抑制剂的杂环化合物 |
| WO2019170055A1 (zh) * | 2018-03-05 | 2019-09-12 | 上海海和药物研究开发有限公司 | 具有cdk4/6激酶抑制活性的化合物、其药用组合物和用途 |
| EA202191938A1 (ru) * | 2019-01-29 | 2021-10-13 | Бета Фарма, Инк. | Производные 2h-индазола в качестве терапевтических средств при видах рака головного мозга и метастазах в головной мозг |
| US20220315532A1 (en) | 2019-06-21 | 2022-10-06 | Gan & Lee Pharmaceuticals Co., Ltd. | Methods for preparing cdk4/6 inhibitor and salt and intermediate thereof |
| AR119184A1 (es) * | 2019-06-21 | 2021-12-01 | Gan & Lee Pharmaceuticals | Sales de un compuesto, formas cristalinas de las sales y método de preparación y uso de las mismas |
| CN116113628A (zh) * | 2020-08-31 | 2023-05-12 | 甘李药业股份有限公司 | 一种含cdk4/6抑制剂的药物组合物 |
| AU2021401403A1 (en) * | 2020-12-18 | 2023-07-13 | Prelude Therapeutics Incorporated | Cdk inhibitors and their use as pharmaceuticals |
| WO2022218247A1 (zh) * | 2021-04-12 | 2022-10-20 | 甘李药业股份有限公司 | 作为cdk4/6抑制剂的氘代化合物 |
| CN117337284A (zh) * | 2021-05-17 | 2024-01-02 | 甘李药业股份有限公司 | 一种cdk4/6抑制剂的医药用途 |
| CN118119393A (zh) * | 2021-09-14 | 2024-05-31 | 甘李药业股份有限公司 | 一种cdk4/6抑制剂的医药用途 |
| CN118339157A (zh) * | 2021-12-24 | 2024-07-12 | 江苏恒瑞医药股份有限公司 | 氢化吲哚类化合物、其制备方法及其在医药上的应用 |
| CN115093397B (zh) * | 2022-06-07 | 2023-09-05 | 自贡市第三人民医院 | 一种用于治疗肿瘤的化合物、合成方法及应用 |
| WO2024051717A1 (zh) * | 2022-09-08 | 2024-03-14 | 上海深势唯思科技有限责任公司 | 作为plk1抑制剂的化合物及其制备方法和用途 |
| WO2024066986A1 (zh) * | 2022-09-30 | 2024-04-04 | 楚浦创制（武汉）医药科技有限公司 | 2-氨基嘧啶类化合物及其应用、药用组合物 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9619284D0 (en) | 1996-09-16 | 1996-10-30 | Celltech Therapeutics Ltd | Chemical compounds |
| KR20020084116A (ko) | 2000-02-07 | 2002-11-04 | 애보트 게엠베하 운트 콤파니 카게 | 2-벤조티아졸릴 우레아 유도체 및 이의 단백질 키나제억제제로서의 용도 |
| GEP20063909B (en) | 2002-01-22 | 2006-08-25 | Warner Lambert Co | 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES |
| EP1713793A4 (en) | 2004-02-04 | 2009-09-02 | Smithkline Beecham Corp | PYRIMIDINONE COMPOUNDS SUITED AS KINASEINHIBITORS |
| KR20080110998A (ko) | 2006-01-30 | 2008-12-22 | 엑셀리시스, 인코포레이티드 | Ｊａｋ２ 조절자로서 ４아릴２아미노피리미딘 또는 4아릴２아미노알킬피리미딘 및 이들을 포함하는 약제학적 조성물 |
| WO2008124085A2 (en) | 2007-04-03 | 2008-10-16 | Exelixis, Inc. | Methods of using combinations of mek and jak-2 inhibitors |
| WO2009017838A2 (en) * | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
| US8309566B2 (en) * | 2008-02-15 | 2012-11-13 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases |
| AU2009248233A1 (en) * | 2008-05-16 | 2009-11-19 | F. Hoffmann-La Roche Ag | Inhibitors of JNK |
| JO2885B1 (en) * | 2008-12-22 | 2015-03-15 | ايلي ليلي اند كومباني | Protein kinase inhibitors |
| UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
| WO2013173506A2 (en) * | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
| EP2909194A1 (en) * | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| CN106608879A (zh) | 2015-10-27 | 2017-05-03 | 甘李药业股份有限公司 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
| CN106810536A (zh) * | 2015-11-30 | 2017-06-09 | 甘李药业股份有限公司 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
| EP3679043B9 (en) | 2017-09-05 | 2023-09-27 | Neumora Therapeutics, Inc. | Vasopressin receptor antagonists and products and methods related thereto |
| WO2022218247A1 (zh) | 2021-04-12 | 2022-10-20 | 甘李药业股份有限公司 | 作为cdk4/6抑制剂的氘代化合物 |
-
2015
- 2015-11-30 CN CN201510856641.1A patent/CN106810536A/zh active Pending
-
2016
- 2016-11-28 RU RU2018122864A patent/RU2749437C2/ru active
- 2016-11-28 EP EP16869945.2A patent/EP3385262B1/en active Active
- 2016-11-28 MX MX2018006370A patent/MX2018006370A/es unknown
- 2016-11-28 DK DK16869945.2T patent/DK3385262T3/da active
- 2016-11-28 IL IL259711A patent/IL259711B/en unknown
- 2016-11-28 MA MA42341A patent/MA42341B2/fr unknown
- 2016-11-28 UA UAA201806447A patent/UA124001C2/uk unknown
- 2016-11-28 KR KR1020187017438A patent/KR20180083421A/ko active IP Right Grant
- 2016-11-28 US US15/778,812 patent/US11091476B2/en active Active
- 2016-11-28 PT PT168699452T patent/PT3385262T/pt unknown
- 2016-11-28 WO PCT/CN2016/107455 patent/WO2017092635A1/zh active Application Filing
- 2016-11-28 CN CN202111217526.1A patent/CN113956238B/zh active Active
- 2016-11-28 JP JP2018546737A patent/JP6921101B2/ja active Active
- 2016-11-28 HU HUE16869945A patent/HUE060152T2/hu unknown
- 2016-11-28 CA CA3002884A patent/CA3002884A1/en active Pending
- 2016-11-28 BR BR112018010879-0A patent/BR112018010879A2/pt not_active Application Discontinuation
- 2016-11-28 ES ES16869945T patent/ES2928169T3/es active Active
- 2016-11-28 CN CN201680064053.7A patent/CN108290864B/zh active Active
- 2016-11-28 AU AU2016365366A patent/AU2016365366B2/en active Active
-
2018
- 2018-04-23 PH PH12018550049A patent/PH12018550049A1/en unknown
- 2018-05-28 ZA ZA2018/03531A patent/ZA201803531B/en unknown
- 2018-06-06 CO CONC2018/0005854A patent/CO2018005854A2/es unknown
-
2021
- 2021-06-08 JP JP2021095588A patent/JP2021138737A/ja active Pending
- 2021-07-30 US US17/444,109 patent/US11787801B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018550049A1 (en) | Protein kinase inhibitor, preparation method and medical use thereof | |
| UA109698C2 (xx) | Похідні азаіндазолу або діазаіндазолу як медикамент | |
| EA201590345A1 (ru) | Способы лечения рака с использованием 3-(4-((4-(морфолинометил)бензил)окси)-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона | |
| CA2925624C (en) | Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | |
| EA201290237A1 (ru) | Киназные ингибиторы | |
| EA201691939A1 (ru) | Способ лечения рака с использованием 3-(5-амино-2-метил-4-оксо-4h-хиназолин-3-ил)пиперидин-2,6-диона | |
| TW201613593A (en) | Molecules for administration to ROS1 mutant cancer cells | |
| RU2015143610A (ru) | Лечение катаплексии | |
| PH12015500313A1 (en) | Orally administered medical composition | |
| JP2013010792A5 (es) | ||
| EA201591753A1 (ru) | 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh | |
| EA201270373A1 (ru) | Ингибиторы jak2 и их применение для лечения миелопролиферативных заболеваний и злокачественной опухоли | |
| EA200970611A1 (ru) | Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы | |
| JP2012530779A5 (es) | ||
| MX2013012588A (es) | Inhibidores de cinasa. | |
| AR080871A1 (es) | Tieno[3,2-b]piridinas sustituidas como inhibidores de la actividad de la proteina tirosina quinasa | |
| GB201302704D0 (en) | Therapeutic compounds | |
| MX2018013325A (es) | Derivados de adenina como inhibidores de proteína quinasa. | |
| CA2831932A1 (en) | Combinations of akt and mek inhibitor compounds, and methods of use | |
| BR112022010181A2 (pt) | Composto tri-heterocíclico como inibidor de jak e uso do mesmo | |
| JP2017503753A5 (es) | ||
| JP2014512355A5 (es) | ||
| MX2024000807A (es) | Inhibidor de aak1 y uso de este. | |
| EA201171087A1 (ru) | СПОСОБЫ ВВЕДЕНИЯ (4aR,10aR)-1-н-ПРОПИЛ-1,2,3,4,4a,5,10,10a-ОКТАГИДРОБЕНЗО[g]ХИНОЛИН-6,7-ДИОЛА И РОДСТВЕННЫХ СОЕДИНЕНИЙ ЧЕРЕЗ СЛИЗИСТУЮ ОБОЛОЧКУ ПОЛОСТИ РТА, СЛИЗИСТУЮ ОБОЛОЧКУ НОСА ИЛИ КОЖУ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ | |
| CY1120608T1 (el) | Φαρμακευτικως δραστικες ενωσεις |